Companies

Cipla in global pact with US company for muscle relaxant

Our Bureau Mumbai | Updated on January 15, 2018 Published on April 06, 2017

MEDRx is eligible to receive up to $30 million through upfront and developmental, regulatory and commercial milestones payments, a note from Cipla said.

Drugmaker Cipla Ltd has entered into a global licensing agreement (except for East Asia) with MEDRx Company Ltd to develop and commercialise MRX-4TZT, a Tizanidine1 patch for the management of spasticity.

MEDRx is eligible to receive up to $30 million through upfront and developmental, regulatory and commercial milestones payments, a note from Cipla said. MEDRx will also receive tiered royalties on the net sales of commercialised licenced products.

MRX-4TZT is a medicated patch that uses ILTS (Ionic Liquid Transdermal System), an exclusive MEDRx technology to deliver Tizanidine, a centrally acting muscle relaxant.

MEDRx has concluded early stage phase-I trials in the US.

Annual sales of muscle relaxants in the US is pegged at $807 million in 2016. And MRX-4TZT is expected to be the first transdermal muscle relaxant worldwide.

Delivering Tizanidine through the skin rather than orally is expected to improve patient experience with better efficacy and a reduction of adverse events and side effects linked to the drug, the company said.

Cipla plans to initiate late stage or phase-III clinical trials after completion of additional phase-I studies, it added.

Published on April 06, 2017
This article is closed for comments.
Please Email the Editor